Unlocking the hypolipidemic potential of bioactive peptides derived from probiotic fermented cattle, camel, goat, and sheep milk: a comprehensive investigation through in vitro,in silico, and molecular docking studies
In vitro and in silico study demonstrates pancreatic lipase inhibition by probiotic fermented milk peptides, suggesting therapeutic value against hypercholesterolemia.
Key Points
Probiotic fermentation of animal milk yields novel bioactive peptides with potent hypolipidemic activity, driven by effective inhibition of pancreatic lipase enzymes.
Pediococcus pentosaceus MF000957 generated the highest pancreatic lipase inhibition during 14 days of refrigerated storage, yielding seven active drug-like peptides.
In silico molecular docking confirms that these non-toxic bioactive peptides possess high binding affinity, highlighting their therapeutic potential against hypercholesterolemia.